Stevens Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Stevens Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-76,820	Closed	-$10.1M	–	835
2019 Q2	$10.1M	Buy	76,820 +48,802	+174%	+$6.29M	0.45%	51
2019 Q1	$3.79M	Sell	28,018 -73,835	-72%	-$9.18M	0.16%	172
2018 Q4	$9.92M	Buy	+101,853	New	+$12M	0.51%	37
2018 Q1	–	Sell	-12,660	Closed	-$1.51M	–	1062
2017 Q4	$1.51M	Sell	12,660 -1,321	-9%	-$161K	0.06%	352
2017 Q3	$1.96M	Sell	13,981 -53,407	-79%	-$7.26M	0.07%	314
2017 Q2	$8.2M	Buy	+67,388	New	+$7.84M	0.31%	103
2017 Q1	–	Sell	-3,884	Closed	-$475K	–	1178
2016 Q4	$475K	Sell	3,884 -25,287	-87%	-$3.09M	0.02%	593
2016 Q3	$3.58M	Sell	29,171 -21,621	-43%	-$2.78M	0.15%	180
2016 Q2	$5.93M	Buy	+50,792	New	+$7.21M	0.24%	122
2015 Q2	–	Sell	-88,222	Closed	-$15.3M	–	1312
2015 Q1	$15.3M	Buy	88,222 +59,232	+204%	+$10.7M	0.54%	47
2014 Q4	$5.36M	Sell	28,990 -7,294	-20%	-$1.35M	0.18%	149
2014 Q3	$6.02M	Sell	36,284 -155,151	-81%	-$25.5M	0.18%	154
2014 Q2	$29.9M	Buy	191,435 +183,913	+2,445%	+$29M	0.8%	15
2014 Q1	$1.14M	Buy	+7,522	New	+$1.2M	0.03%	455

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stevens Capital Management's ALXN Position: Q3 2019 in Review

Stevens Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 76,820 shares — an estimated $10.1M sold.

Stevens Capital Management first reported a position in ALXN in Q1 2014 and held it in 14 quarters. The position peaked at $29.9M in Q2 2014. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Stevens Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Stevens Capital Management sold 76,820 Alexion Pharmaceuticals shares in Q3 2019, an estimated $10.1M.
Stevens Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 14 quarters.
Stevens Capital Management's Alexion Pharmaceuticals position peaked at $29.9M in Q2 2014.
648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Stevens Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.